MX342927B - Mimeticos sinteticos de mir-34. - Google Patents

Mimeticos sinteticos de mir-34.

Info

Publication number
MX342927B
MX342927B MX2013008945A MX2013008945A MX342927B MX 342927 B MX342927 B MX 342927B MX 2013008945 A MX2013008945 A MX 2013008945A MX 2013008945 A MX2013008945 A MX 2013008945A MX 342927 B MX342927 B MX 342927B
Authority
MX
Mexico
Prior art keywords
mir
mimics
strand
sequence
double
Prior art date
Application number
MX2013008945A
Other languages
English (en)
Other versions
MX2013008945A (es
Inventor
Kelnar Kevin
Brown David
Original Assignee
Mirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirna Therapeutics Inc filed Critical Mirna Therapeutics Inc
Publication of MX2013008945A publication Critical patent/MX2013008945A/es
Publication of MX342927B publication Critical patent/MX342927B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a los métodos y composiciones que involucran miméticos de mir-34, incluyendo miméticos de miR-34 y de mir-34c. En algunas modalidades, existen moléculas de ARN de doble hebra con nucleótidos modificados que tienen una hebra activa con la secuencia miR-34 y una hebra pasajera complementaria. En modalidades adicionales, existen moléculas de ARN de doble hebra con nucleótidos modificados que tienen una hebra activa con la secuencia mir-34c y una hebra pasajera complementaria.
MX2013008945A 2011-02-03 2012-02-03 Mimeticos sinteticos de mir-34. MX342927B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439280P 2011-02-03 2011-02-03
PCT/US2012/023755 WO2012106591A1 (en) 2011-02-03 2012-02-03 Synthetic mimics of mir-34

Publications (2)

Publication Number Publication Date
MX2013008945A MX2013008945A (es) 2014-01-08
MX342927B true MX342927B (es) 2016-10-19

Family

ID=45592829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008945A MX342927B (es) 2011-02-03 2012-02-03 Mimeticos sinteticos de mir-34.

Country Status (16)

Country Link
US (3) US8586727B2 (es)
EP (2) EP2670850B1 (es)
JP (2) JP2014506791A (es)
KR (1) KR20140020900A (es)
CN (1) CN103476931A (es)
AU (1) AU2012212023B9 (es)
BR (1) BR112013019853A2 (es)
CA (1) CA2825981A1 (es)
CL (1) CL2013002195A1 (es)
IL (1) IL227697A0 (es)
MX (1) MX342927B (es)
MY (1) MY165507A (es)
RU (1) RU2615117C2 (es)
SG (2) SG192252A1 (es)
WO (1) WO2012106591A1 (es)
ZA (1) ZA201306518B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2503743T3 (es) * 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US8846631B2 (en) 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
SG192252A1 (en) 2011-02-03 2013-09-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
CN108977446A (zh) * 2011-11-18 2018-12-11 阿尔尼拉姆医药品有限公司 修饰的RNAi试剂
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
US20140309278A1 (en) 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
WO2014209970A1 (en) 2013-06-24 2014-12-31 Mirna Therapeutics, Inc. Biomarkers of mir-34 activity
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
CN112646812A (zh) * 2013-12-27 2021-04-13 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens
EP3176269B1 (en) * 2014-07-29 2020-12-02 Wellmarker Bio Co., Ltd. Inhibitors of met and igsf1 for treating cancer
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2016081773A2 (en) * 2014-11-19 2016-05-26 Mirna Therapeutics, Inc. Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
ES2926369T3 (es) 2015-03-27 2022-10-25 Bonac Corp Molécula de ácido nucleico monocatenario que tiene función de suministro y capacidad de control de la expresión génica
CN109312341B (zh) * 2016-03-07 2024-02-27 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
CN105779452A (zh) * 2016-03-10 2016-07-20 上海吉玛制药技术有限公司 一种抑制肿瘤生长的寡聚核酸及其应用
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN107699565B (zh) * 2017-11-24 2020-05-22 苏州大学 微小rna及其在制备抗肿瘤药物中的应用
EP3626820A1 (en) * 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Anticancer compositions containing mirna mimics and uses thereof
AU2021246530A1 (en) 2020-04-02 2022-11-03 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0497875B1 (en) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ATE167523T1 (de) 1990-05-11 1998-07-15 Microprobe Corp Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
DE4204650C1 (es) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
ATE155467T1 (de) 1993-03-30 1997-08-15 Sanofi Sa Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
ATE397001T1 (de) * 2000-02-10 2008-06-15 Mitsui Chemicals Inc Verfahren zur selektiven herstellung eines 1- phosphoryliertem zuckerderivativ-anomers und verfahren zur herstellung von nukleosiden
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
EP1504126B1 (en) 2002-05-03 2014-02-26 Duke University A method of regulating gene expression
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
WO2004076622A2 (en) 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005047505A2 (en) 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
CA2556435C (en) 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP2471922A1 (en) 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
ES2503743T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US7074622B2 (en) 2004-11-15 2006-07-11 Eastman Kodak Company Method and system for sorting and separating particles
EP2468890B1 (en) 2006-01-05 2014-03-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers of the breast or lung
CA2671299A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
JP5145557B2 (ja) * 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
EP2147122B1 (en) * 2007-04-20 2014-07-16 Sigma-Tau Rare Diseases S.A. Enzymatic anticancer therapy
AU2008247427A1 (en) * 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising miR34 therapeutic agents for treating cancer
CA2689974A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
AU2008318778B2 (en) 2007-10-29 2014-10-02 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
JP2010268690A (ja) * 2009-05-19 2010-12-02 Nippon Kayaku Co Ltd 抗腫瘍活性を持つ化合物の感受性の判定方法
SG192252A1 (en) 2011-02-03 2013-09-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
CN103186763B (zh) 2011-12-28 2017-07-21 富泰华工业（深圳）有限公司 人脸识别系统及方法

Also Published As

Publication number Publication date
MX2013008945A (es) 2014-01-08
RU2013140634A (ru) 2015-03-10
AU2012212023A1 (en) 2013-09-12
SG10201600836PA (en) 2016-03-30
EP2670850A1 (en) 2013-12-11
CN103476931A (zh) 2013-12-25
MY165507A (en) 2018-03-28
US9371526B2 (en) 2016-06-21
US8586727B2 (en) 2013-11-19
AU2012212023B9 (en) 2017-01-12
AU2012212023B2 (en) 2017-01-05
BR112013019853A2 (pt) 2017-03-21
EP2670850B1 (en) 2016-10-26
EP3178932A1 (en) 2017-06-14
ZA201306518B (en) 2014-05-28
KR20140020900A (ko) 2014-02-19
US20160053264A1 (en) 2016-02-25
WO2012106591A1 (en) 2012-08-09
RU2615117C2 (ru) 2017-04-04
US20120288933A1 (en) 2012-11-15
SG192252A1 (en) 2013-09-30
CL2013002195A1 (es) 2014-05-30
IL227697A0 (en) 2013-09-30
JP2016152804A (ja) 2016-08-25
CA2825981A1 (en) 2012-08-09
US20140107182A1 (en) 2014-04-17
JP2014506791A (ja) 2014-03-20

Similar Documents

Publication Publication Date Title
MX342927B (es) Mimeticos sinteticos de mir-34.
MX354267B (es) Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
EA201401337A1 (ru) Доставка в лёгкие матричной рнк
CL2015001054A1 (es) Métodos de cultivo de microorganismos en condiciones mixotrópicas no axénicas.
GB2513732A (en) Methods and compositions for sample identification
HK1211319A1 (en) Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor rna
HK1203077A1 (en) Modified nucleoside, nucleotide, and nucleic acid compositions
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
HK1179628A1 (zh) 用部分單鏈的供體分子進行的靶向基因組修飾
WO2013083999A3 (en) Nano-enhanced elastomers
EP2742470A4 (en) SYSTEM AND METHODS FOR RELEVANT BUSINESS NETWORKING BASED ON GROUPS, RESPONSIBILITY AND MEASURED PERFORMANCE WITH TAXED RELEVANCE
IL237898B (en) Systems for cell culture in 3D, and methods for their preparation and uses
CL2015000752A1 (es) Nuevos ligandos de rig-i y metodos para producirlos
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
BR112014001258A2 (pt) método de tipagem de dna, e, conjuntos de iniciadores para tipagem de dna
BR112013010551A8 (pt) variantes de isopreno sintase para produção aprimorada de isopreno
BR112012024049A2 (pt) interferência de rna em indicações dérmicas e fibróticas
IN2015DN00636A (es)
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
IN2015KN00073A (es)
HK1163162A1 (en) Key genes, micrornas, or other non-coding rnas, and the combination thereof for characterizing or regulating cell pluripotency microrna rna
EP2905330A4 (en) CELL CULTIVATION ELEMENT AND CELL CULTIVATION METHOD
WO2012112512A3 (en) Small interfering rnas with target-specific seed sequences
IN2014DN10038A (es)
EP2748320A4 (en) COMPOSITIONS, PROCESSES AND KITS FOR NUCLEIC ACID HYBRIDIZATION

Legal Events

Date Code Title Description
FG Grant or registration